Journal article · 2022 · Open access
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
OncoImmunology, 11(1), 2030135 · Published 16 February 2022 · DOI 10.1080/2162402x.2022.2030135
In brief
“An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation” is a 2022 journal article by Alexander Muik and 20 co-authors, published in OncoImmunology. OpenAlex counts 28 citations as of 18 November 2026, which puts it in the top 5% of works published in 2022 by citations. It is open access under a CC BY-NC licence: the full text is free to read at OncoImmunology.
- Citations
- 28
- Most cited in
- 2026 (9)
- Field-weighted impact
- 1.93
- References
- 46
- Authors
- 21
Abstract
Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis have changed the treatment paradigm for advanced solid tumors; however, many patients experience treatment resistance. In preclinical models 4-1BB co-stimulation synergizes with ICI by activating cytotoxic T- and NK-cell-mediated anti-tumor immunity. Here we characterize the mechanism of action of a mouse-reactive Fc-inert PD-L1×4-1BB bispecific antibody (mbsAb-PD-L1×4-1BB) and provide proof-of-concept for enhanced anti-tumor activity. In reporter assays mbsAb-PD-L1×4-1BB exhibited conditional 4-1BB agonist activity that was dependent on simultaneous binding to PD-L1. mbsAb-PD-L1×4-1BB further blocked the PD-L1/PD-1 interaction independently of 4-1BB binding. By combining both mechanisms, mbsAb-PD-L1×4-1BB strongly enhanced T-cell proliferation, cytokine production and antigen-specific cytotoxicity using primary mouse cells in vitro. Furthermore, mbsAb-PD-L1×4-1BB exhibited potent anti-tumor activity in the CT26 and MC38 models in vivo, leading to the rejection of CT26 tumors that were unresponsive to PD-L1 blockade alone. Anti-tumor activity was associated with increased tumor-specific CD8+ T cells and reduced regulatory T cells within the tumor microenvironment and tumor-draining lymph nodes. In immunocompetent tumor-free mice, mbsAb-PD-L1×4-1BB treatment neither induced T-cell infiltration into the liver nor elevated liver enzymes in the blood. Dual targeting of PD-L1 and 4-1BB with a bispecific antibody may therefore address key limitations of first generation 4-1BB-agonistic antibodies, and may provide a novel approach to improve PD-1/PD-L1 checkpoint blockade.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Muik, A., Altıntaş, I., Gieseke, F., Schoedel, K. B., Burm, S. M., Toker, A., Salcedo, T. W., Verzijl, D., Eisel, D., Grunwitz, C., Kranz, L. M., Vormehr, M., Satijn, D. P. E., Diken, M., Kreiter, S., Sasser, K., Ahmadi, T., Türeci, Ö., Breij, E. C., . . . Sahin, U. (2022). An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation. OncoImmunology, 11(1), 2030135. https://doi.org/10.1080/2162402x.2022.2030135
MLA 9
Muik, Alexander, et al. “An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.” OncoImmunology, vol. 11, no. 1, 2022, p. 2030135. https://doi.org/10.1080/2162402x.2022.2030135.
Chicago
Muik, Alexander, Işıl Altıntaş, Friederike Gieseke, Kristina B Schoedel, Saskia M Burm, Aras Toker, Theodora W. Salcedo, et al. 2022. “An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.” OncoImmunology 11 (1): 2030135. https://doi.org/10.1080/2162402x.2022.2030135.
Harvard
Muik, A. et al. (2022) ‘An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation’, OncoImmunology, 11(1), p. 2030135. doi:10.1080/2162402x.2022.2030135.
IEEE
A. Muik et al., “An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation,” OncoImmunology, vol. 11, no. 1, p. 2030135, 2022, doi: 10.1080/2162402x.2022.2030135.
BibTeX
@article{muik2022inert,
title = {{An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation}},
author = {Muik, Alexander and Altıntaş, Işıl and Gieseke, Friederike and Schoedel, Kristina B and Burm, Saskia M and Toker, Aras and Salcedo, Theodora W. and Verzijl, Dennis and Eisel, David and Grunwitz, Christian and Kranz, Lena M and Vormehr, Mathias and Satijn, David P. E. and Diken, Mustafa and Kreiter, Sebastian and Sasser, Kate and Ahmadi, Tahamtan and Türeci, Özlem and Breij, Esther C.W. and Jure-Kunkel, Maria and Sahin, Ugur},
journal = {OncoImmunology},
year = {2022},
volume = {11},
number = {1},
pages = {2030135},
doi = {10.1080/2162402x.2022.2030135},
url = {https://doi.org/10.1080/2162402x.2022.2030135}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 4 | |
| 2023 | 4 | |
| 2024 | 7 | |
| 2025 | 4 | |
| 2026 | 9 |
Its field-weighted citation impact is 1.93: it has been cited 1.93 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- bispecific antibodies
- PD-L1
- 4-1BB
- immune checkpoint blockade
- PD-1/PD-L1 axis
- antitumor immunity
- CD8+ T cells
- regulatory T cells
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Muik, A., Altıntaş, I., Gieseke, F., Schoedel, K. B., Burm, S. M., Toker, A., Salcedo, T. W., Verzijl, D., Eisel, D., Grunwitz, C., Kranz, L. M., Vormehr, M., Satijn, D. P. E., Diken, M., Kreiter, S., Sasser, K., Ahmadi, T., Türeci, Ö., Breij, E. C., . . . Sahin, U. (2022). An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation. OncoImmunology, 11(1), 2030135. https://doi.org/10.1080/2162402x.2022.2030135
How many times has this paper been cited?
28 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at OncoImmunology: sign in and open the PDF from this page.
Who wrote this paper?
Alexander Muik, Işıl Altıntaş, Friederike Gieseke, Kristina B Schoedel, Saskia M Burm, Aras Toker, Theodora W. Salcedo, Dennis Verzijl, David Eisel, Christian Grunwitz, Lena M Kranz, Mathias Vormehr and 9 more.
What is the DOI of this paper?
10.1080/2162402x.2022.2030135, permanently at https://doi.org/10.1080/2162402x.2022.2030135. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.